Curative Therapeutics Market Size to Reach US$ 44.95 Billion by 2033 - Exclusive Report by DataM Intelligence

Curative therapeutics market reached US$ 19.94 Billion in 2024 from US$ 18.34 Billion in 2023 and is expected to reach US$ 44.95 Billion by 2033, growing at a CAGR of 9.5% during the forecast period 2025-2033.

Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/curative-therapeutics-market?sg

Mergers & acquisitions 2025
✅ Eli Lilly → Verve Therapeutics - Lilly agreed to acquire Verve (deal ≈ $1.0-1.3B depending on CVRs) to secure VERVE-102 and gene-editing capability for one-time cardiovascular treatments. Announced/closed in mid-2025 (deal coverage June-July 2025).

✅ AstraZeneca → EsoBiotec - AstraZeneca entered agreement to acquire EsoBiotec (in-vivo cell therapy / ENaBL platform) to accelerate cell therapies delivered in vivo - strategic move into curative cell therapy modalities (March 2025).

✅ Bluebird Bio → Carlyle & SK Capital (take-private) - Bluebird (gene-therapy developer) agreed to be taken private amid financial stress (deal reported Feb 2025); significant because it affects commercialization and scaling of curative gene therapies.

Curative Therapeutics Market Key Drivers
➠ Rising Prevalence of Chronic and Genetic Disorders
Increasing cases of cancer, rare genetic diseases, and infectious conditions are fueling demand for curative treatments that go beyond symptomatic relief.

➠ Advancements in Gene and Cell Therapy
Breakthroughs in gene editing technologies, regenerative medicine, and cell-based therapies are accelerating the development of long-term or permanent cures.

➠ High R&D Investments and Clinical Trials
Pharmaceutical and biotech companies are allocating substantial resources toward curative drug pipelines, supported by academic research collaborations and government funding.

➠ Regulatory Support and Fast-Track Approvals
Favorable regulatory frameworks in developed markets, including accelerated approval pathways for breakthrough therapies, are boosting innovation and commercialization.

➠ Growing Patient Demand for One-Time Treatments
Patients and healthcare providers are increasingly inclined toward therapies offering lasting benefits, reducing the need for prolonged medication and hospital visits.

➠ Strategic Collaborations and Partnerships
Collaborations between biotechnology firms, healthcare institutions, and research organizations are expediting the translation of novel discoveries into market-ready therapies.

Make an customize enquiry for purchasing this Report @ https://www.datamintelligence.com/customize/curative-therapeutics-market?sg

Curative Therapeutics Market Segments:
By Therapy Type (Biology-Modifying Drugs, Gene Therapies, Cell Therapies and Others)
By Indication (Oncology, Rare Genetic Disorders, Infectious Diseases, Hematology, Ophthalmology, Neurology, Cardiometabolic Disorders and Others)
By End-User (Hospitals, Specialty Clinics, Academic and Research Institutes and Others)
By Regions (North America, Europe, Asia-Pacific, South America and the Middle East & Africa)

Curative Therapeutics Market - Geographical Share
The global curative therapeutics market is witnessing strong growth across major regions, driven by rising demand for advanced treatment options and accelerated drug development initiatives.

North America holds the largest share due to high healthcare expenditure, advanced clinical research infrastructure, and rapid adoption of novel curative therapies. The U.S. leads the region, supported by strong regulatory support for innovative treatments and high prevalence of chronic and genetic disorders.

Europe represents a significant share, propelled by government-backed healthcare programs, expanding biotechnology hubs, and the availability of advanced treatment facilities. Countries such as Germany, the UK, and France are major contributors.

Asia-Pacific is expected to show the fastest growth, driven by increasing investments in biotechnology research, growing incidence of cancer and rare diseases, and expanding patient access to innovative therapies in countries like China, India, and Japan.

Latin America and Middle East & Africa are gradually expanding markets, supported by improving healthcare infrastructure, growing collaborations with global pharmaceutical players, and increasing patient awareness.

Stay informed with the latest industry insights-start your subscription now: https://www.datamintelligence.com/reports-subscription?sg

Market Key Players:
Key players are Gilead Sciences Inc, Spark Therapeutics Inc., Pfizer Inc, Amgen Inc, Novartis Pharmaceuticals Corporation, bluebird bio Inc. and Sarepta Therapeutics Inc.

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.